Denis Burger - Cytodyn Vice Chairman and Chief Science Officer
CYDY Stock | USD 0.16 0.01 5.88% |
Chairman
Dr. Denis R. Burger, Ph.D., is Director of CytoDyn Inc. Consideration of his nomination was recommended to the Nominating and Governance Committee by the Companys Chief Executive Officer. He is also currently a director of Lorus Therapeutics, Inc., a cancer therapeutics company listed on the TSX, and serves on its audit committee. Dr. Burger cofounded Trinity Biotech PLC, a NASDAQ listed diagnostic company, in June 1992, served as its Chairman from June 1992 to May 1995, and is currently lead independent director. Until March 2007, he was Chairman and Chief Executive Officer of AVI Biopharma Inc., a NASDAQ listed RNA therapeutics company. He was also a cofounder of Epitope Inc., serving as its Chairman from 1981 to 1990. Dr. Burger previously held a professorship in the Department of Microbiology and Immunology and Surgery at the Oregon Health and Sciences University in Portland. Dr. Burger received his undergraduate degree in Bacteriology and Immunology from the University of California, Berkeley and his MS and Ph.D. degrees in Microbiology and Immunology from the University of Arizona. Dr. Burger brings significant biotechnology company experience and operational expertise to our Board, as well as a local presence for in person consultations with management. . since 2014.
Age | 79 |
Tenure | 10 years |
Phone | 360 980 8524 |
Web | https://www.cytodyn.com |
Cytodyn Management Efficiency
The company has return on total asset (ROA) of (1.4819) % which means that it has lost $1.4819 on every $100 spent on assets. This is way below average. Cytodyn's management efficiency ratios could be used to measure how well Cytodyn manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 11 records | CHAIRMAN Age | ||
Leonard Laufer | Albertsons Companies | 53 | |
Wesley Taylor | Albertsons Companies | 72 | |
Thomas Bradbury | Smith Douglas Homes | 79 | |
Elkin Pianim | Albertsons Companies | N/A | |
John Warehime | Hanover Foods | 86 | |
John Eaves | Albertsons Companies | 57 | |
Nick Caporella | National Beverage Corp | 88 | |
Philip Heasley | Albertsons Companies | 65 | |
Kamal Hatoum | BBB Foods | 60 | |
James Chapman | Albertsons Companies | 53 | |
Christopher Atayan | AMCON Distributing | 64 |
Management Performance
Return On Asset | -1.48 |
Cytodyn Leadership Team
Elected by the shareholders, the Cytodyn's board of directors comprises two types of representatives: Cytodyn inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytodyn. The board's role is to monitor Cytodyn's management team and ensure that shareholders' interests are well served. Cytodyn's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytodyn's outside directors are responsible for providing unbiased perspectives on the board's policies.
Bernie PMP, VP Operations | ||
Denis Burger, Vice Chairman and Chief Science Officer | ||
Scott Kelly, Chairman of the Board | ||
Nitya Ray, CTO and Head of Process Sciences, Manufacturing & Supply Chain | ||
Carl Dockery, Director | ||
Bruce Montgomery, Independent Director | ||
Michael Mulholland, CFO, Treasurer, Corporate Secretary | ||
David Welch, Director | ||
Antonio CPA, Treasurer CFO | ||
Nader Pourhassan, CEO and President and Director | ||
Richard Pestell, Vice Chairman of the Board and Chief Medical Officer | ||
Cyrus MBA, President | ||
George Bitar, Head Director | ||
Marek Ciszewski, Managing Director | ||
Jordan Naydenov, Independent Director | ||
Anthony Caracciolo, Chairman of the Board | ||
Robert Schatz, Managing Director | ||
Gregory Gould, Independent Director | ||
Kush Dhody, VP Operations | ||
Cristina Leon, Investors | ||
Michael Klump, Independent Director |
Cytodyn Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cytodyn a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset | -1.48 | |||
Current Valuation | 286.7 M | |||
Shares Outstanding | 832.97 M | |||
Shares Owned By Insiders | 7.91 % | |||
Shares Owned By Institutions | 0.06 % | |||
Price To Earning | (3.14) X | |||
Price To Book | 1,066 X | |||
Price To Sales | 1,174 X | |||
Revenue | 266 K | |||
Gross Profit | (73.28 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytodyn in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytodyn's short interest history, or implied volatility extrapolated from Cytodyn options trading.
Pair Trading with Cytodyn
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytodyn position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytodyn will appreciate offsetting losses from the drop in the long position's value.Moving against Cytodyn OTC Stock
0.48 | MSFT | Microsoft Fiscal Quarter End 31st of March 2024 | PairCorr |
0.47 | TRV | The Travelers Companies Fiscal Quarter End 31st of March 2024 | PairCorr |
0.47 | VZ | Verizon Communications Aggressive Push | PairCorr |
0.42 | IBM | International Business Fiscal Quarter End 31st of March 2024 | PairCorr |
The ability to find closely correlated positions to Cytodyn could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytodyn when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytodyn - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytodyn to buy it.
The correlation of Cytodyn is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytodyn moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytodyn moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytodyn can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytodyn. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Cytodyn information on this page should be used as a complementary analysis to other Cytodyn's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Cytodyn OTC Stock analysis
When running Cytodyn's price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
CEOs Directory Screen CEOs from public companies around the world | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Stocks Directory Find actively traded stocks across global markets |